← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
English Aron R.
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001770436
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 0
- Purchases · 24M
- 6
- Average purchase
- $1.9M
- Median purchase
- $272.8K
- Gross purchase value
- $11.4M
Companies: Anebulo Pharmaceuticals, Inc. | CULP INC
6 SEC accession(s) · 6 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2025-03-20 | CULP INC | CULP | 10% Owner | $672.3K | Open filing |
| 2025-03-17 | CULP INC | CULP | 10% Owner | $117.2K | Open filing |
| 2025-03-12 | CULP INC | CULP | 10% Owner | $428.4K | Open filing |
| 2024-12-26 | Anebulo Pharmaceuticals, Inc. | ANEB | Director | 10% Owner | $10.0M | Open filing |
| 2024-12-20 | CULP INC | CULP | 10% Owner | $70.5K | Open filing |
| 2024-12-11 | CULP INC | CULP | 10% Owner | $85.4K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 0/4
- Large purchase ≥ $100k
- 4/6
- Cluster buying · 15D
- 6/6
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.